Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The authors have declared that no competing interest exists
Ceci L, Han Y, Krutsinger K, Baiocchi L, Wu N, Kundu D, Kyritsi K, Zhou T, Gaudio E, Francis H, et al
A new real-world study from Embla, presented at the European Congress on Obesity (ECO) 2025 , shows that our members lost an average of 16.7% of their body weight after 64 weeks using less than half the standard dose of semaglutide (Wegovy) typically used in clinical trials
Both medications reduce appetite through different mechanisms, and combining them could increase side effects without proportionally better results
Exercising regularly, eating more fiber and drinking lots of water
Available evidence suggests retatrutide may drive substantial fat-mass reduction, and a recent body-composition substudy reported that the proportion of lean-mass loss relative to total weight loss was similar to other obesity treatments
US$ 26.85
US$ 28.75
US$ 24.95
US$ 25.39
:max_bytes(150000):strip_icc()/alpha-lipoic-acid-88727-final-a73284168ec14df7a43f74d620dce23d.png)
/assets/images/provider/photos/2800172.png)
